Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inhibitors Clear all
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tinengotinib, abiraterone acetate with prednisone, Enzalutamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
atorvastatin, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced May 22, 2026, 12:51 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 74 Years · Male only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
54
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced May 22, 2026, 12:51 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
264
States / cities
Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced May 22, 2026, 12:51 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced May 22, 2026, 12:51 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes Mellitus
Interventions
Beta-hydroxy-butyrate
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced May 22, 2026, 12:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Diabetes, HIV Infections, Insulin Resistance
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 72 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced May 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Atrophic Vaginitis, Breast Cancer
Interventions
Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 22, 2026, 12:51 AM EDT
Approved For Marketing No phase listed Expanded access
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced May 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Nelfinavir mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
7
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Dermatologic Complication
Interventions
Doxycycline, Management of Therapy Complications, Placebo, Questionnaire Administration, Spironolactone, Sunscreen, Therapeutic Hydrocortisone
Drug · Procedure · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Urbana, Illinois • Des Moines, Iowa • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
Interventions
Empagliflozin 10 MG
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
Interventions
Computed Tomography, Dual X-ray Absorptiometry, Physical Examination, Quality-of-Life Assessment, Questionnaire Administration, Cabozantinib, Lenvatinib
Procedure · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HIV Infections
Interventions
indinavir sulfate, ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced May 22, 2026, 12:51 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Hemophilia A
Interventions
OBI-1
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
6 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215, lenalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced May 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI, CBT
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced May 22, 2026, 12:51 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Orange, California • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 12:51 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
16
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced May 22, 2026, 12:51 AM EDT